NM_054012.4:c.970G>A
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_054012.4(ASS1):c.970G>A(p.Gly324Ser) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000514 in 1,613,900 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 16/28 in silico tools predict a damaging outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G324V) has been classified as Likely pathogenic.
Frequency
Consequence
NM_054012.4 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- citrullinemia type IInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Myriad Women’s Health, G2P
- acute neonatal citrullinemia type IInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- adult-onset citrullinemia type IInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ASS1 | ENST00000352480.10 | c.970G>A | p.Gly324Ser | missense_variant, splice_region_variant | Exon 12 of 15 | 1 | NM_054012.4 | ENSP00000253004.6 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152076Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000358 AC: 9AN: 251184 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.0000540 AC: 79AN: 1461824Hom.: 0 Cov.: 33 AF XY: 0.0000523 AC XY: 38AN XY: 727218 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152076Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74302 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Citrullinemia type I Pathogenic:10
The c.970G>A impacts a highly conserved nucleotide (phyloP: 9.18) and a highly conserved amino acid (down to the yeast). It has 2 occurrences in gnomAD v4. Prediction tools pedict a deleterious effect (20/21), CADD : 34, REVEL 0.970. It is predicted to alter splicing (SpliceAI : donor loss 0.67). In vitro data revealed complete loss of enzyme activity (residual activity <2%) (PMID: 18473344). Despite having a severe impact on enzyme activity in vitro, the variant was reported in two asymptomatic patients with citrullinemia type 1, one was hmozygote for the variant and the second was compound heterozygote with the c.40G>A p.(Gly14Ser) variant (PMID: 14680976). It was also reported in a Korean cohort with neonatal onset (1 to 16d, in trans with c.421-2A>G) or later onset (3m, in trans with c.421-2A>G or c.1128-6_1188dup67) (PMID: 23246278). Our patient (mild form of ASSD) carries the c.808G>C variant in cis with c.206T>C, inherited from his father, and in trans with c.970G>A, inherited from his mother. Intriguingly, the paternal allele of our patient is composed of the two variants reported in PMID: 11708871, which are presumably in trans in the published patient (severe case). There is second published patient who also carries the same two variants with no reported segregation (PMID: 12815590). In gnomAD, c.206T>C and c.808G>C have the same number of occurrences (v2.1.1 : 2-2, v4.0.0 : 5-5). These two variant might be on the same haplotype and we postulate that there is a third variant in trans that was not found in the first published case (PMID: 11708871). This would explain why our patient has a mild phenotype resulting from an hypomorphic allele c.970G>A (PMID: 14680976) + a severe allele [c.206T>C;c.808G>C].
This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM2,PM3,PP3,PP4.
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.004%). Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.97; 3Cnet: 0.88). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000006327 /PMID: 2358466 /3billion dataset).The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 12815590, 16475226). A different missense change at the same codon (p.Gly324Val) has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000458676 /PMID: 19006241). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
Citrullinemia Pathogenic:2
This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 324 of the ASS1 protein (p.Gly324Ser). This variant also falls at the last nucleotide of exon 13, which is part of the consensus splice site for this exon. This variant is present in population databases (rs121908639, gnomAD 0.01%). This missense change has been observed in individual(s) with citrullinemia (PMID: 2358466, 11211875, 12815590, 14680976, 18473344). ClinVar contains an entry for this variant (Variation ID: 6327). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). For these reasons, this variant has been classified as Pathogenic.
Variant summary: ASS1 c.970G>A (p.Gly324Ser) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 251184 control chromosomes. c.970G>A has been reported in the literature in numerous individuals affected with Citrullinemia Type I, in the homozygous and compound heterozygous state (examples: Gao_2003, Haberle_2003, Lee_2013, etc). These data indicate that the variant is very likely to be associated with disease. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
ASS1-related disorder Pathogenic:1
The ASS1 c.970G>A variant is predicted to result in the amino acid substitution p.Gly324Ser. This variant has been reported in the homozygous state or heterozygous state with a second causative ASS1 variant in multiple individuals with citrullinaemia type I; in at least one patient, it was found in trans with a pathogenic variant (Kobayashi et al. 1990. PubMed ID: 2358466; Hong et al. 2000. PubMed ID: 10987146; Gao et al. 2003. PubMed ID: 12815590; Häberle et al. 2003. PubMed ID: 14680976; Bijarnia-Mahay et al. 2018. PubMed ID: 30285816). In one study of a group of patients with classic citrullinemia, it was found on 4 of 45 independent alleles, though additional genetic information was not provided on those patients (Berning et al. 2008. PubMed ID: 18473344). In an E. coli expression study, the p.Gly324Ser substitution reduced enzyme activity to <2% (Berning et al. 2008. PubMed ID: 18473344). Additionally, the c.970G nucleotide is the last nucleotide in exon 13 of the ASS1 gene, and the c.970G>A variant is predicted to impact splicing at the adjacent canonical splice donor site (SpliceAI, Jaganathan et al. 2019. PubMed ID: 30661751). This variant is reported in 0.014% of alleles in individuals of Latino descent in gnomAD. In summary, this variant is interpreted as pathogenic.
not provided Pathogenic:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at